ライフサイエンスコーパス: Cmax

1 Cmax, volume of distribution/bioavailability (Vd/F), and

2 ithin equivalence limits (AUC 90% CI 98-103, Cmax 90% CI 99-105), showing that lamotrigine exposures

3 TFV AUC0-24h, Cmax, and Ctrough decreased by 33%, 30%, and 34%, respec

4 r the concentration-time curve (AUC) by 35%, Cmax by 28%, and Cmin by 46%, consistent with induction

5 or log-transformed variables: AUC0-96, 2.58; Cmax, 0.64; and AUC0-infinity, 4.05; P >/= .13) and that

6 terval, .59-1.42), Ctrough 0.95 (0.57-1.59), Cmax 0.87 (0.57-1.33).

7 the predicted oral dose of CsA-ME produced a Cmax > 700 ng/ml in 90% of patients from days 2 to 4, an

8 the predicted oral dose of CsA-GC produced a Cmax > 700 ng/ml in only 64 and 82% of patients during t

9 ents with the marketed daily capsule, with a Cmax that is no higher than the daily product.

10 out significantly exceeding the median adult Cmax.

11 met for all product comparisons for AUC and Cmax in both individuals with a kidney transplant and th

12 linearly related to the chylomicron AUC and Cmax values for alpha-carotene, lycopene, phylloquinone,

13 a linear increase in the chylomicron AUC and Cmax values for beta-carotene.

14 4.65%-118.13% and 80.00%-125.00% for AUC and Cmax, respectively.

15 under the concentration-time curve (AUC) and Cmax were seen with linear increases in administered dos

16 under-the-concentration-time-curve [AUC] and Cmax) for rifampicin, isoniazid, pyrazinamide, and etham

17 rd trimester, geometric mean TAF AUClast and Cmax were decreased by 46% and 52%, respectively, compar

18 h combination, tenofovir GM (CV%) AUCtau and Cmax remained below reference values in adults taking 25

19 s, resulting in relative bioavailability and Cmax values 10- and 8.4-fold higher, respectively, confi

20 ent with a CrCl of 23.8 ml/min, the Cmin and Cmax were 0.32 and 0.7 microg/ml, respectively, with an

21 /ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respect

22 With CrCl of <10 ml/min, the mean Cmin and Cmax were 0.75+/-0.42 and 1.59+/-0.55 microg/ml, respect

23 /ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respect

24 Significantly higher AUC, SUV, and Cmax were observed in tumors in phase I studies.

25 tration to in vitro response ratio approach (Cmax/AC50), analogous to decision-making methods for cli

26 The 90% CIs of the ratios of both Cmax and AUC were within equivalence limits (AUC 90% CI

27 The maximum concentration Cmax and area under the concentration-time curve (AUC) f

28 influence RIF AUC and maximum concentration (Cmax) at a dose of 20 mg/kg, despite an extreme distribu

29 The mean maximum concentration (Cmax) at a reasonably well-tolerated dose (50 mg orally

30 60-fold reduction in maximum concentration (Cmax) compared with cota immediate release (IR) SC formu

31 than 0.05 mumol/L and maximum concentration (Cmax) of paclitaxel.

32 range) plasma arsenic maximum concentration (Cmax) was 0.28 microM (0.11-0.37 microM) and at 0.2 mg/k

33 DTG maximum concentration (Cmax) was significantly higher in patients >=60 years ol

34 centration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/

35 e curve (AUC) and the maximum concentration (Cmax) were calculated for TAF and tenofovir and compared

36 ours (AUC(0-24h)) and maximum concentration (Cmax) were calculated.

37 icant accumulation in maximum concentration (Cmax), and the intersubject variabilities (coefficient o

38 the curve (AUC0-24), maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time tha

39 l exposure (AUC0-24), maximum concentration (Cmax), CSF concentration, and grade 3-5 adverse events.

40 me curve and maximum observed concentration (Cmax) and first RPV thigh injection Cmax and all last RP

41 posure (AUC) rather than peak concentration (Cmax) or time above MIC.

42 exposure (AUC(0-t) ) and peak concentration (Cmax) ratios of generic and reference formulations durin

43 Temsirolimus peak concentration (Cmax), and sirolimus Cmax and area under the concentrati

44 n post-dose to establish peak concentration (Cmax), and standard antimicrobial minimal inhibitory con

45 on postdose to establish peak concentration (Cmax), and standard antimicrobial minimum inhibitory con

46 d concentration (C[av]), peak concentration (Cmax), and time to Cmax (tmax) values were calculated fr

47 rates IC(50), slope, and peak concentration (Cmax), correlated with improved complete cytogenetic res

48 The peak concentration (Cmax)/MIC versus log10 colony-forming units (CFU)/mL red

49 bolites with a maximum plasma concentration (Cmax) 1 hour after ingestion.

50 Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC)

51 comparison of maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC)

52 increased the maximal plasma concentration (Cmax) and area under the time-concentration curve in rat

53 se with a mean maximum plasma concentration (Cmax) of 5.97 +/- 2.25 microg/mL and an area under the c

54 The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was

55 urve (AUC) and maximum plasma concentration (Cmax) were determined.

56 AUC), maximum observed plasma concentration (Cmax), and time above a threshold concentration.

57 /PK1 of EFV400 maximum plasma concentration (Cmax), area under the curve (AUC), and concentration at

58 n steady-state maximum plasma concentration (Cmax,ss) and area under the steady-state plasma concentr

59 eight-adjusted maximum plasma concentration (Cmax/dose/kg) were detected overall such that the 25 mg

60 .359, P=.023), maximum plasma concentration (Cmax; r2=0.340, P=.028), and plasma HIV RNA decline.

61 D showed a mean maximum serum concentration (Cmax) of 1,209 +/- 430 ng/mL, with a median T1/2 beta fo

62 The median maximum serum concentration (Cmax), area under the curve from 0-8 hours (AUC0-8), tim

63 serum half-life (and maximum concentration [Cmax]) generally increased between the first and fourth

64 apolated to infinity, maximum concentration [Cmax], and time to Cmax) were observed on Day 10 in subj

65 geometric mean maximum plasma concentration [Cmax] and 77% and 82% lower AUC0-t [area under the curve

66 an 176 nM (the maximal plasma concentration [Cmax] with recommended adult dose) in 76% of samples, wh

67 to 72 h, as well as maximal concentrations (Cmax: 2.04 +/- 0.14 compared with 2.73 +/- 0.18 mumol/L)

68 Peak concentrations (Cmax) on day 1 related to mean percentage decrement in n

69 Higher peak concentrations (Cmax) or exposure (AUC) to rifampicin or isoniazid in ep

70 that produced maximal plasma concentrations (Cmax) of less than 1% of RTD-1 levels required for in vi

71 time in which maximum plasma concentrations (Cmax) were achieved averaged 1.22 hours with an average

72 oxicity, maximum radiotracer concentrations (Cmax) in brain and vertebra were low (0.67 and 0.54 m(2)

73 d plasma d6-alpha-tocopherol concentrations (Cmax) and the areas under the curve increased 2- and 3-f

74 AUC for 4-OH-CPA, the finding that 4-OH-CPA Cmax may determine its level of myelotoxicity indicates

75 Furthermore, monitoring 4-OH-CPA Cmax may identify individuals at most risk of CPA side e

76 (0.11-0.37 microM) and at 0.2 mg/kg per day, Cmax was 0.40 and 0.46 microM; area under the concentrat

77 apparent clearance, volume of distribution, Cmax, AUCinf, and full concentration-time profiles.

78 (356+/-63), and 2 hr after the morning dose (Cmax=1567+/-669), decreased from 39+/-16 to 15+/-8 and 3

79 is 24% at a dose of 2 mg/kg with a mean drug Cmax of 145 +/- 46 ng/mL.

80 DTG Cmax was significantly higher in older PLWH.

81 eneral, maximal levels of DNA scission (i.e. Cmax) varied over a considerably larger range than did t

82 differed by >15% for 17% of pairs; estimated Cmax differed by >15% for 39%.

83 cant differences in maximum urine excretion (Cmax) by sex were observed for only 6 metabolites and di

84 High-level expansion (Cmax 127,152 copies/ug genomic DNA) and durable CAR-T pe

85 deling generated estimates of drug exposure (Cmax and AUC) from individual-level post hoc Bayesian es

86 elling generated estimates of drug exposure (Cmax and AUC) from individual-level post-hoc Bayesian es

87 appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.

88 5%) and AUC (27.4%) and, to a lesser extent, Cmax (11%).

89 the 82 patients was 101.1 to 114.5% and for Cmax was 83.0% to 112.7%.

90 for area under the curve (AUC0-24h), and for Cmax, 0.93 (.77-1.13).

91 Except for Cmax, which was 19.5% higher after IV drug administratio

92 nce limits (lowest and highest CI limits for Cmax, 92.6% and 110.4%; for AUC0-96, 96.9% and 101.9%).

93 lidations as the prediction errors (%PE) for Cmax and AUC were less than 15%.

94 content in the plasma chylomicron fraction (Cmax).

95 Efficacy was not associated with gentamicin Cmax or MIC.

96 Twenty-six percent of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and i

97 ocktail + Delta9-THC + CBD produced a higher Cmax and area under the plasma concentration vs time cur

98 91.4% and yield of 68.3%, and 4-fold higher Cmax and AUC over the slow-releasing ATRA formulation.

99 ere able to increase the penetration (higher Cmax) and the residence time of bevacizumab into the bra

100 imiting neutropenia had significantly higher Cmax values than patients who did not, whereas nonhemato

101 ent of variation [CV], approximately 40%) in Cmax and area under the concentration-time curve from 0

102 increased by 40%, despite a 30% decrease in Cmax.

103 0-fold lower exposure and 3-fold decrease in Cmax.

104 AMP resulted in a dose-dependent increase in Cmax and AUC(0-24h) of 2F-ara-A and achieved an AUC(0-24

105 consumption correlated with the increase in Cmax when felodipine was taken with either the 1st or th

106 Intersubject variability in Cmax and AUC(0-t) was small and similar for reference an

107 Interpatient variability in Cmax,ss and AUCtau,ss was estimated to be 65% and 71% re

108 okinetic evaluation in dogs showed increased Cmax (39.18 +/- 7.34 vs 21.68 +/- 6.3 mug.dL-1), higher

109 te prodrugs led to a substantially increased Cmax and prolonged availability of FimH antagonists in u

110 mer conjugate did not produce a high initial Cmax of SN-38.

111 tration (Cmax) and first RPV thigh injection Cmax and all last RPV thigh injection parameters were st

112 a with no subject x formulation interaction (Cmax, 0.00; AUC0-96, 0.54; and AUC0-infinity, 0.36; P >/

113 fied negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture co

114 /PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which ther

115 If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the ison

116 For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associat

117 Faster RBT clearance and low Cmax in 3 participants on RBT+RAL requires further study

118 is of plasma AZD5582 levels revealed a lower Cmax in treated infants compared to adults (294 ng/mL ve

119 12.11-15.81) and the concentration maximum (Cmax) (range 17.96-24.72) for all products.

120 time of 48 hours and concentration maximum (Cmax) of 4000- to 15,000-fold higher than their therapeu

121 125 was rapidly absorbed with geometric mean Cmax and AUC0-24 h values of 1417 ng/mL and 16 727 h ng/

122 For the CI regimen at MTD, the mean Cmax was 963 +/- 473 ng/mL, with a median T1/2 beta for

123 C was 285.6 +/- 46.4 microg/mL.min with mean Cmax values of 3.38 +/- 0.43 microg/mL at 75 mg/m2.

124 , maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time that concentrations per

125 ng/h per mL), Caverage (8.8 +/- 4.2 ng/mL), Cmax (19.2 +/- 9.7 ng/mL), apparent Half-life (11.7 +/-

126 stat AUC0-24 on Day 1 was 851 (282) ng*h/ml; Cmax of 58.1 (26.4) ng/ml was achieved at a median tmax

127 oncentrations peaked at approximately 50 nM (Cmax) and remained elevated for several hours.

128 A 2- to 4-fold greater dose-normalized Cmax was observed for the dog compared to the other spec

129 The GMR of Cmax, AUC0-t, and AUC0-infinity for IVM, DEC, ALB-SOX, a

130 Food affected variability of Cmax but not AUC(0-t) .

131 The peak (Cmax) was significantly higher after the morning dose th

132 prednisolone concentration in the perfusate (Cmax) by 3.0 and 2.2 fold, respectively.

133 GMRs (90% CI) of PK3/PK2 and PK3/PK1 Cmax, AUC, and C24h were 0.95 (.86-1.05) and 0.92 (.83-1

134 VOO, FVOO increased IRH (P<0.05) and plasma Cmax of hydroxytyrosol sulphate, a metabolite of OOPC 2h

135 lmitic acid conjugation increases ASO plasma Cmax and improved delivery of ASO to interstitial space

136 MEC ratio, and peak concentration in plasma [Cmax]:MEC ratio) at clinically achievable exposures.

137 In our Neoral-treated sample population, Cmax was associated with the least variable "cyclosporin

138 curve (AUC), maximum concentration postdose (Cmax), minimum concentration postdose (Cmin), time to ma

139 nt toxicokinetic (TK) model to first predict Cmax for in vivo corroboration using therapeutic scenari

140 lted in an improved pharmacokinetic profile (Cmax = 359 ng.h/mL; AUC0-t = 2436 ng.h/mL) and a desirab

141 evealed that poor systemic exposure in rats (Cmax = 44 ng/mL; AUC0-t = 359 ng . h/mL) at 10 mg/kg was

142 er, although 3 participants in arm C had RBT Cmax <250 ng/mL.

143 The in vitro PK/PD relationship Cmax/MIC versus log10 CFU/mL reduction followed a sigmoi

144 isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagon

145 ctions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture conversion.

146 ARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which there is concentration-d

147 PK for 400 mg (day 7) showed Cmax 3.07 muM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hour

148 mus peak concentration (Cmax), and sirolimus Cmax and area under the concentration-time curve were de

149 No differences in initial slope, Cmax, area under curve (AUC), and T1/2 of BNA were found

150 ated by greater values of the initial slope, Cmax, AUC, and shorter T1/2 than men (all ps<0.04).

151 tions differed by <15% in 99% of BE studies; Cmax differed by <15% in 89% of studies.

152 nd optimal dosing regimens, using 2 targets: Cmax at 3-6 mg/L and area under the curve (AUC) >= 10.52

153 The Cmax : MEC ratio appears to be the parameter most closel

154 The Cmax and Tmax of ziconotide in CSF following intravenous

155 The Cmax was used as a measure of oral bioavailability to al

156 The Cmax/MIC associated with stasis was 2.1 for C. albicans

157 (90% confidence interval, 1.10-1.23) and the Cmax ratio was 1.49 (90% confidence interval, 1.35-1.65)

158 1/2 for 4-OH-CPA was increased 1.8-fold, the Cmax reduced 1.7-fold, and the AUC remained unchanged.

159 ; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L

160 cellized lutein, PLGA-NP lutein improved the Cmax in rat plasma by 15.6-fold and in selected tissues

161 r-individual variability was observed in the Cmax and Tmax of many of these compounds in both plasma

162 At a CPA dose of 100 mg/kg, the Cmax, plasma area under the curve (AUC) and half-life we

163 of MFE for 7 days significantly reduced the Cmax of midazolam from 919 +/- 70 ng / mL to 708 +/- 91

164 Pharmacokinetics in mice suggested the Cmax to be 12.0 +/- 2.5 mug/mL and 170 +/- 10 ng/mL in t

165 was found to be closely correlated with the Cmax of 4-OH-CPA (r2= 0.80, P = 0.002).

166 These Cmax values were 4- to 15-fold lower than their cytotoxi

167 The mean time to Cmax (9 +/- 2 h), fractional disappearance rates (0.022

168 av]), peak concentration (Cmax), and time to Cmax (tmax) values were calculated from paired intraveno

169 h low intraindividual variation) and time to Cmax were dose independent.

170 y, maximum concentration [Cmax], and time to Cmax) were observed on Day 10 in subjects receiving tedu

171 of plasma disappearance but similar times to Cmax.

172 he curve from 0-8 hours (AUC0-8), time until Cmax (Tmax), and half-life for moxifloxacin were 3.08 (I

173 in pharmacokinetic parameters estimated were Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and

174 in dogs provided modest bioavailability with Cmax = 0.22 microg/mL.

175 at specific sites correlated inversely with Cmax values, indicating that maximal levels of etoposide

176 files were very similar in both species with Cmax decreasing and Tmax increasing with increasing fatt